Study links brain blood flow changes to Alzheimer's risk

New research from the University of Southern California suggests that subtle declines in brain blood flow and oxygen delivery may be early indicators of Alzheimer's disease. The study, published in Alzheimer's and Dementia, used noninvasive scans to connect vascular health with amyloid plaques and hippocampal shrinkage. These findings highlight the role of brain circulation in the disease process beyond traditional markers like amyloid and tau.

Researchers at the Mark and Mary Stevens Neuroimaging and Informatics Institute at the Keck School of Medicine of USC conducted a study on older adults, both with and without cognitive impairment. The work, detailed in the journal Alzheimer's and Dementia: The Journal of the Alzheimer's Association, explored how brain blood flow and oxygen use relate to established Alzheimer's signs.

The team employed transcranial Doppler ultrasound to measure blood velocity in major brain arteries and near-infrared spectroscopy to assess oxygen delivery to cortical tissue. By applying mathematical modeling, they created indicators of cerebrovascular function, which adjust to fluctuations in blood pressure and carbon dioxide.

Participants with vascular function similar to cognitively healthy adults showed lower amyloid levels and larger hippocampi, both associated with reduced Alzheimer's risk. Those with mild cognitive impairment or dementia exhibited weaker vascular performance.

"Amyloid and tau are often considered the primary players in Alzheimer's disease, but blood flow and oxygen delivery are also critical," said Amaryllis A. Tsiknia, the study's lead author and a USC PhD candidate. "Our results show that when the brain's vascular system functions more like it does in healthy aging, we also see brain features that are linked to better cognitive health."

Meredith N. Braskie, PhD, the senior author and assistant professor of neurology, noted: "These vascular measures are capturing something meaningful about brain health. They appear to align with what we see on MRI and PET scans that are commonly used to study Alzheimer's disease."

Arthur W. Toga, PhD, director of the Stevens INI, added: "These findings add to growing evidence that Alzheimer's involves meaningful vascular contributions in addition to classic neurodegenerative changes."

The methods are less invasive and costly than MRI or PET scans, potentially enabling broader screening. However, the study provides a cross-sectional view and does not prove causation. Long-term research is underway to monitor if vascular changes predict cognitive decline.

The study was supported by the National Institutes of Health and the National Institute on Aging.

Liittyvät artikkelit

A scientist in a lab analyzing a blood sample for early Alzheimer's detection, with brain scan overlays.
AI:n luoma kuva

Blood test can reveal Alzheimer's signs years ahead

Raportoinut AI AI:n luoma kuva

A new study shows that blood tests can detect signs of Alzheimer's several years before the disease develops. American researchers published the findings in The Lancet.

Researchers at Boston Children’s Hospital report that mutations commonly associated with clonal blood-cell expansion and some blood cancers were enriched in microglia-like immune cells in Alzheimer’s brains and were also detectable in matched blood samples. The Cell study proposes that age- or injury-related weakening of the blood-brain barrier could allow mutated blood immune cells to enter the brain, potentially amplifying inflammation and contributing to neurodegeneration.

Raportoinut AI Faktatarkistettu

People who reported more mentally stimulating experiences from childhood through older age were less likely to develop Alzheimer’s disease and tended to develop symptoms years later than peers with the lowest enrichment, according to an observational study published in Neurology.

A team of researchers led by Professor Yan-Jiang Wang has published a review arguing that Alzheimer's disease requires integrated treatments targeting multiple factors, not single causes. New drugs like lecanemab and donanemab offer modest benefits by slowing decline, but fall short of reversal. The paper, in Science China Life Sciences, emphasizes genetics, aging, and systemic health alongside amyloid-beta and tau proteins.

Raportoinut AI

A University of California San Francisco study has linked lower but still normal levels of active vitamin B12 to slower thinking and white matter damage in healthy older adults. The research, published in Annals of Neurology in 2025, suggests current guidelines may miss early neurological risks. Researchers examined 231 participants with an average age of 71.

Tämä verkkosivusto käyttää evästeitä

Käytämme evästeitä analyysiä varten parantaaksemme sivustoamme. Lue tietosuojakäytäntömme tietosuojakäytäntö lisätietoja varten.
Hylkää